EUVIMEDEUVIMED entdecken
Crossref

FGFR2 ‐ RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression

María S Rodriguez iD, Yamil D Mahmoud iD, Silvia Vanzulli iD, Sebastián Giulianelli iD, Eunice Spengler, Paula Martínez Vazquez, Javier Burruchaga, John Bushweller iD, Caroline A Lamb iD, Isabel A Lüthy iD, Claudia Lanari iD, Cecilia Pérez Piñero iD

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35302 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von María S Rodriguez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 2, Core Binding Factor Alpha 1 Subunit, Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Fondo para la Investigación Científica y Tecnológica, Consejo Nacional de Investigaciones Científicas y Técnicas, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overcoming luminal breast cancer (BrCa) progression remains a critical challenge for improved overall patient survival. RUNX2 has emerged as a protein related to aggressiveness in triple‐negative BrCa, however its role in luminal tumors remains elusive. We have previously shown that active FGFR2 (FGFR2‐CA) contributes to increased tumor growth and that RUNX2 expression was high in hormone‐independent mouse mammary carcinomas. To elucidate the interaction between FGFR2 and RUNX2 in human BrCa, we investigated their roles in tumor progression and treatment responsiveness. Increased FGFR2 activity resulted in higher RUNX2 expression, cell proliferation, and metastasis. In contrast, silencing FGFR2 reduced these parameters. Overexpression of RUNX2 in FGFR2‐silenced cells rescued the inhibitory effects, promoting a more aggressive phenotype, even if compared with the wt RUNX2‐transfected cells, which also had increased aggressiveness compared with naïve‐transfected cells. RUNX2‐overexpressing tumors were insensitive to endocrine‐ or FGFR inhibitor treatments. Notably, the CBFβ‐RUNX complex inhibitor, AI‐14‐91, demonstrated great effectiveness in vitro . In a small cohort of luminal BrCa patients, nuclear RUNX2 expression was associated with tumor recurrence. Transcriptomic analysis strongly supported these data showing that patients with luminal carcinomas with high RUNX2 activity score have a worse progression‐free interval than those with low RUNX2 activity. Our findings suggest a complex interplay between FGFR2 and RUNX2 in regulating tumor aggressiveness. This study underscores the significance of RUNX2 in luminal BrCa progression and posits RUNX2 as a promising therapeutic target and as a potential prognostic biomarker in luminal BrCa patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Fibroblast Growth Factor, Type 2Core Binding Factor Alpha 1 SubunitBreast NeoplasmsHumansFemaleDisease ProgressionAnimalsMiceCell ProliferationCell Line, TumorGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

FGFRRUNX2breast cancerendocrine resistanceendocrine therapy

Substanzen

Receptor, Fibroblast Growth Factor, Type 2Core Binding Factor Alpha 1 SubunitRUNX2 protein, humanFGFR2 protein, human

Autor:innen und Institutionen

  • Instituto de Biología y Medicina Experimental (IBYME), CONICET, Buenos Aires, Argentina.
  • Instituto de Tecnología (INTEC), Universidad Argentina de la Empresa (UADE), Buenos Aires, Argentina.
  • Instituto de Biología de Organismos Marinos (IBIOMAR-CCT), CENPAT-CONICET, Puerto Madryn, Argentina.
  • Hospital Zonal Gral. de Agudos "Magdalena V. de Martínez", General Pacheco, Argentina.
  • Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia, USA.

ORCID-Profile: María S Rodriguez, Yamil D Mahmoud, Silvia Vanzulli, Sebastián Giulianelli, John Bushweller, Caroline A Lamb, Isabel A Lüthy, Claudia Lanari, Cecilia Pérez Piñero

Förderung

  • Fondo para la Investigación Científica y Tecnológica
  • Consejo Nacional de Investigaciones Científicas y Técnicas
  • NCI NIH HHS
  • Fundación SALES to Claudia Lanari

Zitieren

APA

Rodriguez, M. S., Mahmoud, Y. D., Vanzulli, S., Giulianelli, S., Spengler, E., Martínez Vazquez, P., Burruchaga, J., Bushweller, J., Lamb, C. A., Lüthy, I. A., Lanari, C., & Pérez Piñero, C. (2025). FGFR2 ‐ RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression. International Journal of Cancer. https://doi.org/10.1002/ijc.35302

Vancouver

Rodriguez MS, Mahmoud YD, Vanzulli S, Giulianelli S, Spengler E, Martínez Vazquez P, et al. FGFR2 ‐ RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression. International Journal of Cancer. 2025. doi:10.1002/ijc.35302

BibTeX
@article{Rodriguez2025,
  author = {Rodriguez, María S and Mahmoud, Yamil D and Vanzulli, Silvia and Giulianelli, Sebastián and Spengler, Eunice and Martínez Vazquez, Paula and Burruchaga, Javier and Bushweller, John and Lamb, Caroline A and Lüthy, Isabel A and Lanari, Claudia and Pérez Piñero, Cecilia},
  title = {FGFR2 ‐ RUNX2 activation: An unexplored therapeutic pathway in luminal breast cancer related to tumor progression},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35302}
}
Kostenlos starten →